구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab) Merck·Metastatic Urothelial Carcinoma 6 trials |
|---|---|
Overview Program | Coformulated favezelimab/pembrolizumab |
Overview Company | Merck |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Urothelial Carcinoma |
Overview Indication | Metastatic Urothelial Carcinoma; Urothelial Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior therapies. Studies have shown that blockade of both lymphocyte-activation gene 3 (LAG-3) … |
Clinical Safety signal | A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior therapies. Studies have shown that blockade of both lymphocyte-activation gene 3 (LAG-3) … |
Clinical Selected reported efficacy | ORR 6.8% |
Clinical Reported ORR | 6.8% |
Clinical Result source | ClinicalTrials.gov NCT05064059 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT05064059 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab) Merck·Metastatic Urothelial Carcinoma 6 trials |
|---|---|
Overview Program | Coformulated favezelimab/pembrolizumab |
Overview Company | Merck |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Urothelial Carcinoma |
Overview Indication | Metastatic Urothelial Carcinoma; Urothelial Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior therapies. Studies have shown that blockade of both lymphocyte-activation gene 3 (LAG-3) … |
Clinical Safety signal | A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior therapies. Studies have shown that blockade of both lymphocyte-activation gene 3 (LAG-3) … |
Clinical Selected reported efficacy | ORR 6.8% |
Clinical Reported ORR | 6.8% |
Clinical Result source | ClinicalTrials.gov NCT05064059 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT05064059 |
추천 비교
추천 비교